- Home
- IFRX vs KVAC Comparison
IFRX vs KVAC Comparison
Compare IFRX & KVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- KVAC
- Stock Information
- Founded
- IFRX 2007
- KVAC 2021
- Country
- IFRX Germany
- KVAC United States
- Employees
- IFRX N/A
- KVAC N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- KVAC
- Sector
- IFRX Health Care
- KVAC
- Exchange
- IFRX Nasdaq
- KVAC Nasdaq
- Market Cap
- IFRX 117.8M
- KVAC 120.9M
- IPO Year
- IFRX 2017
- KVAC 2023
- Fundamental
- Price
- IFRX $1.00
- KVAC $11.22
- Analyst Decision
- IFRX Strong Buy
- KVAC
- Analyst Count
- IFRX 2
- KVAC 0
- Target Price
- IFRX $9.00
- KVAC N/A
- AVG Volume (30 Days)
- IFRX 322.6K
- KVAC 11.8K
- Earning Date
- IFRX 05-07-2025
- KVAC 01-01-0001
- Dividend Yield
- IFRX N/A
- KVAC N/A
- EPS Growth
- IFRX N/A
- KVAC 197.31
- EPS
- IFRX N/A
- KVAC 0.41
- Revenue
- IFRX $171,642.00
- KVAC N/A
- Revenue This Year
- IFRX $106.72
- KVAC N/A
- Revenue Next Year
- IFRX $66.89
- KVAC N/A
- P/E Ratio
- IFRX N/A
- KVAC $27.06
- Revenue Growth
- IFRX 162.79
- KVAC N/A
- 52 Week Low
- IFRX $1.01
- KVAC $10.46
- 52 Week High
- IFRX $2.82
- KVAC $11.24
- Technical
- Relative Strength Index (RSI)
- IFRX 33.87
- KVAC 63.43
- Support Level
- IFRX $1.01
- KVAC $11.20
- Resistance Level
- IFRX $1.18
- KVAC $11.14
- Average True Range (ATR)
- IFRX 0.12
- KVAC 0.00
- MACD
- IFRX 0.01
- KVAC -0.00
- Stochastic Oscillator
- IFRX 3.66
- KVAC 71.43
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About KVAC Keen Vision Acquisition Corporation
Keen Vision Acquisition Corp is a blank check company.